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MAGE-A4 has been considered as an attractive cancer-testis (CT) antigen for tumour immunotherapy. It has been well accepted that
T-helper type 1 (Th1) cell-dominant immunity is critical for the successful induction of antitumour immunity in a tumour-bearing host.
The adoptive Th1 cell therapy has been shown to be an attractive strategy for inducing tumour eradication in mouse systems.
However, Th1-cell therapy using human tumour-specific Th1 cells, which were expanded from peripheral blood mononuclear cells
(PBMCs) in a clinically useful protocol, has never been performed. Here, we first identified MAGE-A4-derived promiscuous helper
epitope, peptide (MAGE-A4 280–299), bound to both HLA-DPB1*0501 and DRB1*1403. Using the peptide, we established a
suitable protocol for the propagation of MAGE-A4-specific Th1 cells in vitro. Culture of CD4
þ T cells with IFN-g-treated PBMC-
derived adherent cells in the presence of helper epitope peptide resulted in a great expansion of MAGE-A4-reactive Th cells
producing IFN-g , but not IL-4. Moreover, it was shown that ligation of MAGE-A4-reactive Th1 cells with the cognate peptide caused
the production of IFN-g and IL-2. Thus, our identified MAGE-A4 helper epitope peptide will become a good tool for the propagation
of tumour-specific Th1 cells applicable to adoptive immunotherapy of human cancer.
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Cancer-testis (CT) antigens can be classified into several super
families. MAGE gene group is one of the well-characterised
members of the CT antigen family that includes six subfamilies,
MAGE-A, MAGE-B, MAGE-C, MAGE-D, MAGE-E and MAGE-F. All
of these genes are located on chromosome X. Among these,
MAGE-A, MAGE-B and MAGE-C show expression patterns as CT
antigens (Van der Bruggen et al, 1991; De Plaen et al, 1994;
Chomez et al, 2001). The expression of MAGE-A4 antigen in
tumour has been reported in various human malignancies, ovarian
neoplasms (Yakirevich et al, 2003), mucosal melanomas of the
head and neck (Prasad et al, 2004), oesophageal adenocarcinomas
(Lin et al, 2004), colorectal cancer (Li et al, 2005) and lung cancer
(Tajima et al, 2003). Therefore, MAGE-A4 is one of the attractive
target molecules in tumour immunotherapy.
Previously, we have proposed that tumour-specific CD4
þ
T cells, especially T-helper type 1 (Th1) cells play a critical role
for inducing cytotoxic T lymphocytes (CTL)-mediated antitumour
immunity in tumour-bearing mice (Nishimura et al, 1999; Ikeda
et al, 2004; Chamoto et al, 2006; Zhang et al, 2006). Although many
investigators have centred in the activation and targeting of
tumour-specific CD8
þ CTL and CD4
þ T cells are required for the
priming and maintenance of CD8
þ T cells (Janssen et al,
2003; Smith et al, 2004; Sun et al, 2004). CD4
þ T cells stimulate
CD8
þ T cells through activating antigen-presenting cells (APCs),
such as dendritic cells (DCs) through CD40-CD154 interaction
(Bennett et al, 1998; Schoenbergner et al, 1998). It was also
reported that CD4
þ T cells could stimulate CD8
þ T cells by their
cell–cell communication through cytokines or the direct cell-to-
cell interaction (Lu et al, 2000; Giuntoli et al, 2002). Therefore,
fully activated tumour-specific CD4
þ T cells are important for
inducing an effective immunotherapy of the tumour-bearing hosts.
For this purpose, many helper epitope peptides have been
identified from various tumour antigens (Kobayashi and Celis,
2008). However, there are no reports about helper epitope peptides
in MAGE-A4 molecules though several CTL epitopes have been
identified (Zhang et al, 2002; Miyahara et al, 2005). Thus, we
planned to identify MAGE-A4-derived helper peptide, which will
become a great tool for MAGE-A4-targeted immunotherapy.
Adoptive T-cell therapy is one of the most attractive strategies
for inducing tumour eradication. Adoptive immunotherapy using
tumour-specific CD8
þ T cells isolated from resected tumour tissue
was carried out for long terms, but no good clinical responses were
obtained from these studies (Dudley et al, 2001, 2002b). However,
recently, adoptive cell transfer of CD8
þ T cells contaminated with
CD4
þ T cells into lymphodepleting tumour-patients caused a
great inhibition of tumour growth (Dudley et al, 2002a, 2005). In
that therapy, the investigators reported that the existence of CD4
þ
T cells appeared to be important for inducing an efficient
therapeutic effect. Moreover, it was shown that adoptive cell
transfer of NY-ESO-1-reactive CD4
þ T cells into melanoma
Received 25 November 2009; revised 23 January 2009; accepted 10
February 2009; published online 10 March 2009
*Correspondence: Professor T Nishimura, Division of Immunoregulation,
Section of Disease Control, Institute for Genetic Medicine, Hokkaido
University N15 W7, kita-ku, Sapporo 060-0815, Japan;
E-mail: tak24@igm.hokudai.ac.jp
British Journal of Cancer (2009) 100, 1135–1143
& 2009 Cancer Research UK All rights reserved 0007– 0920/09 $32.00
www.bjcancer.com
M
o
l
e
c
u
l
a
r
D
i
a
g
n
o
s
t
i
c
spatient resulted in a great inhibition of the growth of metastatic
tumour tissue (Hunder et al, 2008). We initially showed the crucial
role of tumour-specific Th1 cells and the cell transfer of tumour-
specific Th1 cells induced tumour-specific CTL in vivo to eradicate
the established tumour mass (Nishimura et al, 1999; Chamoto
et al, 2003). This result raised the possibility that Th1 cell therapy
will become a good strategy for the treatment of human cancer.
Here, we identified new MAGE-A4-derived helper peptides
efficiently presented by APC. The one of the peptides binds to both
HLA-DPB1*0501 and DRB1*1403, indicating that it is a promis-
cuous peptide. Using the peptide, we established a suitable
protocol for the propagation of MAGE-A4-specific CD4
þ T cells
applicable to adoptive Th1-cell therapy of human cancer. More-
over, we showed that helper epitope peptide is a good tool for
the activation of MAGE-A4-specific Th1 cells to produce Th1
cytokines, which will preferable to activate CTL-mediated anti-
tumour immunity. Thus, we believe that our identified MAGE-
A4-specific CD4-helper epitope peptides will become a good tool
for the application to the therapy of human cancer.
MATERIALS AND METHODS
Cell lines and culture medium
Epstein–Barr virus-transformed B cells (EBV-B) were generated
from peripheral blood mononuclear cells (PBMCs) of healthy
volunteers by culturing with culture supernatant from the EBV-
producing B95-8 cell line after obtaining written informed consent
approved by medical ethics committees of Hokkaido University
Graduate School of Medicine. These cells were maintained in RPMI
1640 (Sigma, St Louis, MO, USA) containing 10% heat-inactivated
foetal bovine serum (Life Technologies Inc., Invitrogen, Carlsbad,
CA, USA) with 2mML -glutamine, 0.05mM 2-mercaptoethanol
(Sigma), 10mM HEPES, 100Uml
 1 penicillin, and 100mgml
 1
streptomycin sulphate. Dendritic cells (DC) and T cells were
derived from PBMC of healthy volunteers after obtaining written
informed consent. Dendritic cells were cultured in AIM-V (Life
Technologies) medium without serum. T cells were cultured in
AIM-V medium containing 5% heat-inactivated pooled human AB
serum (kindly donated from Hokkaido red cross blood centre) or
5% heat-inactivated foetal bovine serum (Life Technologies).
Peptides, recombinant protein
Synthetic peptides (purity495%) were purchased from Greiner Bio-
One (Tokyo, Japan). MAGE-A4 overlapping peptides were pur-
chased from SIGMA genosys (Hokkaido, Japan). The 44 overlapping
peptides covering whole amino-acid sequence of MAGE-A4 were
synthesised and designated as M1-M44 peptide (M1-M43: 20-mer
peptide, M44: 17-mer peptide). For the initial screening assay, these
44 peptides were subdivided into MIX1-MIX9 peptides pools (MIX1;
M1-M5, MIX2; M6-M10, MIX3; M11-M15, MIX4; M16-M20, MIX5;
M21-M25, MIX6; M26-M30, MIX7; M31-M35, MIX8; M36-M40, and
MIX9; and M41-M44). Recombinant MAGE-A4 protein was
expressed in Escherichia coli as full-length protein.
Preparation of PBMC-derived dendritic cells as
antigen-presenting cells
Peripheral blood mononuclear cells from healthy volunteers were
isolated by Ficoll-Paque (Amersham Bioscience, Uppsala, Sweden)
gradient centrifugation. Peripheral blood mononuclear cells were
incubated in 6-well plate (Nalge Nunc International, Roskilde,
Denmark) in AIM-V medium without serum. Non-adherent cells
were removed and adherent cells were cultured in the presence of
GM-CSF (30ngml
 1; KIRIN, Tokyo, Japan) and IL-3 (30ngml
 1;
KIRIN) in AIM-V (Sato et al, 1999; Buelens et al, 2002). Medium
was exchanged with fresh medium containing GM-CSF and IL-3 on
days 3. On day 7, the adherent DCs were harvested with trypsine
(Sigma) and used as APC. The expression of CD11c was 499% for
these DCs (data not shown).
In vitro stimulation of helper T cells with recombinant
protein-pulsed DC
CD4
þ T cells were purified from PBMC by EasySep CD4 T-cell
positive selection kit (Veritas, Tokyo, Japan). Dendritic cells,
which were generated from adherent PBMCs by culture with
GM-CSF, and IL-3 in vitro were pulsed with 50mgml
 1 rMAGE-A4
protein for 2h. CD4
þ T cells (1 10
6) were stimulated with
autologous mitomycin C (MMC)–treated antigen-pulsed DC
(1 10
5) in 24-well culture plate (BD Biosciences, San Jose, CA,
USA) in AIM-V medium supplemented with 5% human AB serum.
Seven days later, the stimulated CD4
þ T cells were restimulated
with MMC-treated autologous DC pulsed with rMAGE-A4 protein
(50mgml
 1). Two days after the secondary stimulation with
antigen, human recombinant IL-2 (kindly supplied by Shionogi
Pharmaceutical Institute Co. Ltd, Osaka, Japan) was added at a
final concentration of 10IUml
 1. One week later, the T cells were
divided into nine cultures, and each culture was stimulated with
PBMC pulsed with peptides mixture (MIX1-MIX9), including
MAGE-A4-derived overlapping peptides. After stimulation with
peptides mixture, the T-cell cultures were tested for their cytokine
production in response to peptides mixture. The T cells showing a
specific response to the cognate mixture were expanded and used
for further analysis.
Antigen-specific cytokine production of T cells
T cells (3 10
4 per well) were cultured with or without MMC-
treated autologous PBMC (3 10
4 per well) or EBV-B cells (1 10
4
per well) in the presence of relevant antigen in 96-well culture plate
(BD Biosciences). After 20h, culture supernatants were collected
and cytokine (IFN-g, IL-4, or IL-2) level was measured by ELISA kit
(BD Biosciences). Major histocompatibility complex (MHC)-
restriction was determined by adding anti-HLA-DR monoclonal
antibody (mAb) (L243; BD Bioscience), anti-HLA-DP mAb
(BRAFB6), or anti-HLA-DQ mAb (SPV-L3; Serotech Ltd, Raleigh,
NC, USA). All mAbs were used at a final concentration of 5mgml
 1.
Establishment of the protocol for the induction of
MAGE-A4-specific Th cells useful for clinical therapy
Isolated PBMC was incubated in 24-well culture plate in serum-free
AIM-V medium with 20ngml
 1 IFN-g (PeproTech, Inc, Rocky
Hill, NJ, USA). After 2h, the adherent PBMCs were treated with
MMC. The isolated CD4
þ T cells were cultured with IFN-g-treated
PBMC in the presence of MAGE-A4 peptide (10mgml
 1). Seven
days later, the cultured CD4
þ T cells were restimulated with
IFN-g-treated adherent cells derived from PBMC. Further seven
days later, peptide-pulsed PBMCs were used as APC to expand
peptide-specific Th cells. The expression of cell surface markers of
IFN-g-treated PBMC was determined by staining with fluorescei-
nisothiocyanate (FITC)-conjugated mouse anti-HLA-A/B/C mAb,
FITC-conjugated mouse anti-HLA-DR/DP/DQ mAb, FITC-conju-
gated mouse anti-human CD86mAb, or FITC-conjugated mouse
isotype control mAb (BD Biosciences). The cell-associated
fluorescence was determined by a multicolour flow cytometer
(FACSCalibar, BD Biosciences) and analysed with a computer
software (CellQuest, BD Biosciences).
Measurement of cytokine production by Intracellular
staining assay
The cultured Th cells were stimulated with autologous EBV-B cell
lines in the presence of cognate or irrelevant peptide, respectively.
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samples and the cells were incubated for an additional 4h. The
intracellular cytokine levels of the cells were determined by
staining with R-phycoerythrin (PE)/cyanine-conjugated mouse
anti-human CD4mAb and PE-conjugated mouse anti-human
IL-4mAb and FITC-conjugated mouse anti-human IFN-g mAb
or PE-conjugated mouse anti-human CD8mAb. These antibodies
were purchased from BD Biosciences. The cell-associated
fluorescence was determined by a multicolour flow cytometer
(FACSCalibar, BD Biosciences) and analysed with a computer
software (CellQuest, BD Biosciences).
RESULTS
Identification of MAGE-A4-derived helper epitopes
To identify MAGE-A4-derived helper epitopes, purified CD4
þ
T cells from two healthy donors were stimulated with autologous
monocyte-derived DC pulsed with rMAGE-A4 protein. Then,
specific responses of the cultured CD4
þ Th cells to MAGE-
A4-derived peptide were examined in ELISA. In donor 1, one Th
cell line produced significant IFN-g against autologous PBMCs
pulsed with mixture of MAGE-A4-derived overlapping peptide.
Moreover, it was shown that Th cells produced IFN-g in response
to M38 peptide included in MIX8 (Figure 1A). To elucidate HLA-
restriction of the Th cell line, we used mAb against HLA-DP, HLA-
DQ and HLA-DR. The IFN-g production of Th cell line against M38
peptide was significantly reduced when mAb against HLA-DR was
added, whereas mAbs against HLA-DP or HLA-DQ had no effect
(Figure 1B). To further analyse the HLA-restriction, we tested the
reactivity of Th cells against a range of peptide-pulsed allogeneic
EBV-B cell lines with known HLA-DR genotypes. As shown in
Figure 1C, the Th cells recognised only HLA-DRB1*0101-expres-
sing EBV-B cell lines, suggested that this M38 peptide was
presented by HLA-DRB1*0101.
CD4
þ Th cells derived from donor 2 revealed the specific IFN-g
production in response to autologous PBMC pulsed with M41
peptide (MAGE-A4; AETSYVKVLEHVVRVNARVR) in MIX9. The
response was reduced in the presence of anti-HLA-DP mAb, but
not HLA-DQ nor HLA-DR (Figure 2B). The Th cells recognised
only HLA-DPB1*0501-expressing EBV-B cell lines pulsed with the
M41 peptide, suggested that the M41 peptide was presented by
HLA-DPB1*0501 (Figure 2C). As this allele is expressed in more
than half of the numbers of Japanese, the M41 peptide is very
useful to generate MAGE-A4-specific helper T cells from many
patients. Moreover, M41 peptide-specific Th cell line was also
obtained from donor 3 (Figure 3A). Unlike the case of the donor 2,
this recognition of the CD4
þ T cells was inhibited by anti-HLA-DR
mAb (Figure 3B). Because HLA-DR genotypes of donor 3 are
DRB1*0401 and DRB1*1403, we attempted to use allogeneic EBV-B
cell lines expressing matched genotype. However, we failed to find
any DRB1*1403-expressing cell lines. Therefore, we used
DRB1*1405-expressing cell lines instead of the DRB1*1403-cell
lines. Consequently, the donor 3-derived Th cells showed a specific
reaction to M41 peptide against only autologous cell line, but not
DRB1*0401-expressing allogeneic cell lines (Figure 3C). Thus, the
M41 peptide has capability of binding to HLA-DRB1*1403,
suggesting that the M41 peptide is promiscuous and would be
available with tumour immunotherapy. Therefore, we focused on
this peptide in the further experiments.
Identifying minimal epitopes of MAGE-A4 recognised by
the CD4
þ T-cell lines
To identify MAGE-A4 minimal epitopes recognised by M41-
specific CD4
þ T-cell lines from donor 2 and donor 3, respectively,
a series of 15-mer overlapping peptides derived from M41 peptide
were prepared and tested for their ability to stimulate IFN-g
release from the both T-cell lines. As shown in Figure 4, the
HLA-DPB1*0501-restricted CD4
þ T cells recognised EBV-B cells
in the presence of p4 to p9 peptides, suggesting that this minimal
region was MAGE-A4 284–293 (YVKVLEHVVR; Figure 4, left
panel). In contrast, the HLA-DRB1*1403-restrected CD4
þ T cells
recognised EBV-B cells in the presence of p5 to p9 peptides,
suggesting that this minimal region was MAGE-A4 284–294
(YVKVLEHVVRV; Figure 4, right panel). Thus, there was a little
difference in the epitope recognised by two CD4
þ T-cell lines.
Generation of MAGE-A4-specific CD4
þ T cells by using a
synthetic peptide
We assessed whether a synthetic M41 peptide is able to generate
MAGE-A4-specific CD4
þ T cells. CD4
þ T cells derived from a
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Figure 1 Induction of HLA-DRB1*0101-restricted MAGE-A4-specific
CD4
þ T cells from donor 1. (A) Donor 1-derived CD4
þ T cells were
assessed the specificity to overlapping peptides and their mixture, MIX8.
The CD4
þ T cells were stimulated with autologous PBMC alone ( )o r
PBMC pulsed with MIX8 (10mgml
 1) or with each of overlapping peptide
in the MIX8 (10mgml
 1). HLA types of the donors were displayed over
the panel. (B) M38-specific Th cells were stimulated with autologous
PBMC pulsed with irrelevant (open bar) or cognate (filled bar) peptide in
the presence of 5mgml
 1 of mAbs against HLA-DP, HLA-DQ or HLA-DR.
(C) M38-specific Th cells were stimulated with allogeneic EBV-B cell lines
pulsed with irrelevant (open bar) or cognate (filled bar) peptide. All T-cell
cultures were incubated with the MMC-treated target cells in duplicate for
20–24h, then the culture supernatants were assessed for IFN-g levels in
ELISA. These experiments were carried out independently at least three
times. Data denote mean±s.e.m. and are representative of the
experiments.
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sdonor 4 with HLA-DPB1*0501 were stimulated with their
autologous monocyte-derived DC pulsed with a synthetic M41
peptide. As a result of repetitive stimulation with the peptide, the
CD4
þ T cells produced IFN-g in response to the M41 peptide
bound to HLA-DPB1*0501molecule in APC (Figure 5A and B),
indicating that the synthetic M41 peptide is able to induce MAGE-
A4-specific CD4
þ T cells effectively.
Development of a protocol for the inducing and
propagating peptide-specific Th1 cells applicable to
adaptive immunotherapy
To apply our identified helper epitope peptide to the clinical trial
of Th1-cell therapy, we tried to establish a protocol for the
induction and propagation of MAGE-A4 peptide-specific Th1 cells
useful for Th1 cell therapy. In general, monocyte-derived DC
expanded in vitro are used as APC for stimulating T cells with
peptide. However, it takes approximately 7 days to prepare DC
from PBMC. Therefore, we developed an alternative method. We
used freshly isolated PBMC-derived adherent cells as a source of
APC. The detailed protocol for preparing APC was shown in
Figure 6A. IFN-g-treated adherent cells upregulated its expression
of HLA-class I, HLA-class II and CD86, respectively, compared
with freshly isolated adherent cells (Figure 6B). As shown in
Table 1, the same results were obtained in two donors. Thus, we
evaluated whether IFN-g-treated adherent cells derived from
PBMC had a capability of initiating peptide-induced stimulation
for enhancing the propagation of MAGE-A4 peptide-specific Th1
cells. CD4
þ T cells from PBMC of donor 4 and donor 5 were
primed by each autologous APC in the presence of M41 peptide. As
shown in Figure 7A, peptide-specific CD4
þ T cells were generated
more efficiently when IFN-g-treated adherent cells were used as
DPB1*0201/ DPB1* 0901
DPB1*0201/ DPB1* 0901
DPB1*0402/ DPB1* 0501
DPB1*0201/ DPB1* 0501
DPB1*0501/ DPB1* 0501
0 4000 8000 12000
C
0
25000
20000
15000
10000
M41 peptide (+)
(–) DP (–) DQ
B
DR
5000
5000
4000
3000
0
I
F
N
-

 
l
e
v
e
l
s
 
(
p
g
 
m
l
–
1
)
I
F
N
-

 
l
e
v
e
l
s
 
(
p
g
 
m
l
–
1
)
IFN- levels (pg ml–1)
Donor 2 (DPB1*0201/ DPB1* 0501)
(–) MIX9 M41 M42 M43 M44
A
2000
1000
HLA of APC
Figure 2 Induction of HLA-DPB1*0501-restricted MAGE-A4-specific
CD4
þ T cells from donor 2. (A) Donor 2-derived CD4
þ T cells were
assessed the specificity to overlapping peptides and their mixture, MIX9.
The CD4
þ T cells were stimulated with autologous PBMC alone ( )o r
PBMC pulsed with MIX9 (10mgml
 1) or with each of overlapping peptide
in the MIX9 (10mgml
 1). HLA types of the donor were displayed over the
panel. (B) M41-specific Th cells were stimulated with autologous PBMC
pulsed with irrelevant (open bar) or cognate (filled bar) peptide in the
presence of 5mgml
 1 of mAbs against HLA-DP, HLA-DQ or HLA-DR.
(C) M41-specific Th cells were stimulated with allogeneic EBV-B cell lines
pulsed with irrelevant (open bar) or cognate (filled bar) peptide. All T-cell
cultures were incubated with the MMC-treated target cells in duplicate for
20–24h, then the culture supernatants were assessed for IFN-g levels in
ELISA. These experiments were carried out independently at least three
times. Data denote mean±s.e.m. and are representative of the
experiments.
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Figure 3 Induction of HLA-DRB1*1403-restricted MAGE-A4-specific
CD4
þ T cells from donor 3. (A) Donor 3-derived CD4
þ T cells were
assessed the specificity to overlapping peptides and their mixture, MIX9.
The CD4
þ T cells were stimulated with autologous PBMC alone ( )o r
PBMC pulsed with MIX9 (10mgml
 1) or with each of overlapping peptide
in the MIX9 (10mgml
 1). HLA types of the donor were displayed over the
panel. (B) M41-specific Th cells were stimulated with autologous PBMCs
pulsed with irrelevant (open bar) or cognate (filled bar) peptide in the
presence of 5mgml
 1 of mAbs against HLA-DP, HLA-DQ or HLA-DR.
(C) M41-specific Th cells were stimulated with allogeneic or autologous
EBV-B cell lines pulsed with irrelevant (open bar) or cognate (filled bar)
peptide. All T-cell cultures were incubated with the MMC-treated target
cells in duplicate for 20–24h, then the culture supernatants were assessed
for IFN-g levels in ELISA. These experiments were carried out
independently at least three times. Data denote mean±s.e.m. and are
representative of the experiments.
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were used. Surprisingly, the frequency of peptide-specific CD4
þ
T cells primed with IFN-g-treated adherent cells was almost the
same as that primed with monocyte-derived DC. The generated Th
cells produced much IFN-g and less IL-4 in the presence of cognate
peptide, indicating peptide-specific Th1 cells were dominantly
activated in this condition (Figure 7B). We also showed that
repetitive stimulation of Th1 cells with APC pulsed with MAGE-A4
helper epitope peptide resulted in 10-25-fold increase of the
numbers of Th1 cells within a 28-day culture (Figure 8A). All the
frequencies of helper (CD4-positive) T cells expanded were over
97% (data not shown).
Activation of MAGE-A4-specific Th1 cells with MAGE-A4
helper epitope peptide in the absence of APC
The expanded CD4
þ Th1 cells expressed MHC class II molecules
and costimulatory molecules on their cell surface. Therefore, we
tried whether MAGE-A4 helper epitope peptide could activate Th1
cells to produce IFN-g and IL-2 in the absence of APC. As shown in
Figure 8B, addition of M41 peptide, but not irrelevant peptide to
the samples resulted in the production of IFN-g and IL-2 from
Th1 cells. Moreover, addition of M41 peptide to the mixed
culture of Th1 cells and CD8
þ T cells resulted in the induction of
IFN-g-producing CD8
þ T cells, which is preferable to induce
Th1-dependent antitumour immunity (Figure 8C).
DISCUSSION
Recently, it has been indicated that CD4
þ Th cells play a crucial
role in tumour immunology in addition to CD8
þ CTL in both
animal and human systems (Nishimura et al, 1999; Marzo et al,
2000; Ikeda et al, 2004; Janssen et al, 2005; Hunder et al, 2008).
Indeed, in clinical study, our analysis of specimens from non-small
cell lung carcinoma (NSCLC) showed significant correlations
between infiltration of both CD8
þ and CD4
þ T cells into tumour
nest and prognosis (Yoshida et al, 2006). Thus, it is important to
develop the new immunotherapy, as using HLA class I and
II-binding peptide-based vaccine (Odunsi et al, 2007) or antigen
protein-based vaccine as activating both CD8
þ and CD4
þ effector
T cells (Atanackovic et al, 2004; Uenaka et al, 2007). It has been,
however, known that many regulatory T cells were induced in
tumour-bearing hosts to inhibit effector function of CTL or Th
cells (Liyanage et al, 2002). Therefore, it is difficult to activate these
tumour-specific effector T cells under the suppressive condition in
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Figure 4 Identification of minimal epitopes recognised by two M41 peptide-specific CD4
þ T-cell lines. Two M41 peptide-specific CD4
þ T-cell lines
derived from donors 2 and 3 were cultured with their autologous PBMCs pulsed with a series of 15-mer overlapping peptides encompassing M41 peptide
(MAGE-A4 280–299). The left panel showed reactivity of HLA-DRB1*0501-restricted CD4
þ T-cell lines and the right panel showed HLA-DRB1*1403-
CD4
þ T-cell lines. Each minimal epitope of two cell lines were displayed under their graphs. Each T-cell line was stimulated with the MMC-treated target
cells pulsed with the indicated peptide (10mgml
 1) in duplicate for 20h, then the culture supernatants were assessed for IFN-g levels in ELISA. These
experiments were carried out independently at least three times. Data denote mean±s.e.m. and are representative of the experiments.
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Figure 5 Induction of HLA-DPB1*0501-restricted MAGE-A4-specific
CD4
þ T cells from donor 4 using a synthetic M41 peptide. (A) Donor
4-derived CD4
þ T cells were primed with autologous DC pulsed with
synthetic M41 peptide (10mgml
 1), but not rMAGE-A4 protein. The
primed CD4
þ T cells were stimulated with autologous PBMC pulsed with
irrelevant peptide (open bar) or cognate peptide (filled bar) in the
presence of 5mgml
 1 of mAbs against HLA-DP, HLA-DQ or HLA-DR.
(B) The M41-specific Th cells were stimulated with allogeneic EBV-B-cell
lines pulsed with irrelevant (open bar) or cognate (filled bar) peptide. All
T-cell cultures were incubated with the MMC-treated target cells in
duplicate for 20–24h, then the culture supernatants were assessed for
IFN-g levels in ELISA. These experiments were carried out independently
at least three times. Data denote mean±s.e.m. and are representative
of the experiments.
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sa tumour-bearing host. To overcome the problem, we initially
proposed the application of tumour-specific Th1 cells to adoptive
tumour immunotherapy (Nishimura et al, 1999; Ikeda et al, 2004;
Chamoto et al, 2006; Zhang et al, 2006). It has been well accepted
that Th1-dominant immunity is critical for the successful
induction of antitumour immunity in tumour-bearing hosts
(Trinchieri, 2003 ). Our earlier study in animal models showed
that the transfer of OVA-specific Th1 eradicated the transplanted
OVA-expressing tumour. The spleen cells from mice treated
with OVA-specific Th1 cells contained OVA-specific CTL, whereas
OVA-specific Th2 cell therapy did not induced functional CTL
(Nishimura et al, 1999). Moreover, by the combination therapy of
OVA-specific TCR gene-modified Th1 cells with cyclophospha-
mide, OVA-expressing tumour was completely eradicated
(Chamoto et al, 2004). In addition, in the transfer model of the
gene-modified tumour-specific human T cells into immuno-
deficient mouse, combination treatment with tumour-specific
Tc1 and Th1 completely rejected tumour, although tumour-
specific Tc1 alone did not show such an effect (Gyobu et al,
2004). These results suggest that Th1-cell therapy has the potential
of enhancing antitumour immunity in patients with cancer.
Therefore, we attempted to develop a protocol for the propagation
of tumour-specific human Th1 cells in vitro. The choice of targeted
tumour antigen is of importance in the conduct of clinical trials of
tumour immunotherapy. MAGE-A4 is an attractive antigen
because of its wide expression in a variety of tumours and its
immunogenicity (Tajima et al, 2003; Yakirevich et al, 2003; Lin
et al, 2004; Prasad et al, 2004; Li et al, 2005). Earlier studies
reported the generation of MAGE-A4-specific CTL clones and
definition of its epitope peptides (Zhang et al, 2002; Miyahara et al,
2005). However, no helper epitopes of MAGE-A4 have been
reported. In this study, we first identified the helper epitope
peptides derived from MAGE-A4, which are presented to
DPB1*0501 and DRB1*1403, indicating that this tumour peptide
is a promiscuous peptide (Figure 4). In several tumour antigens,
promiscuous peptides have been identified (Kobayashi et al, 2000;
Ohkuri et al, 2007). Binding ability of these peptides to multiple
HLA could overcome the limitation of HLA restriction of cancer
patients. In addition, as DPB1*0501, which M41 peptide binds to,
is frequently expressed in Japanese population (approximately
60%), it is expected that our defined helper peptide would
contribute to the tumour immunotherapy of patients with MAGE-
A4-expressing tumour.
In this study, we established a protocol for the efficient
induction and propagation of peptide-specific Th1 cells. In most
of adoptive cell therapy so far performed, the injected cells were
mainly expanded from TIL by culturing with anti-CD3 mAb and
high-dose IL-2 (Dudley et al, 2001, 2005). As it is difficult to obtain
TIL from each patient, the strategy has a limitation. To overcome
this limitation, Morgan et al (2006) developed the approach to
therapy based on the genetic modification of PBMC. They reported
that transfer of tumour antigen-specific TCR gene-modified PBL
enhanced antitumour immunity in the patients. Moreover,
Labarriere et al (2008) recently reported that PBMCs were good
sources of CTL as well as TIL. In fact, they had performed adoptive
cell therapy in clinical trial, in which PBMC-derived CTL clones
were used (Vignard et al, 2005). Likewise, our strategy is that
PBMCs are used as sources of CD4
þ T-cell for generating tumour-
specific Th cells. In addition, we used PBMC-derived adherent cells
as antigen-presenting cells. This strategy has the advantage that it
does not take a long time from collection of blood to the initiation
of CD4
þ T-cell sensitisation. Although freshly isolated PBMC-
derived adherent cells had less stimulatory activity, IFN-g-treated
adherent cells showed the upregulated expression of MHC class II
and CD86 costimulatory molecules to acquire stimulatory activity
Class II CD86
IFN- (–)
IFN- (+)
Class I 
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u
n
t
s
Fluorescence intensity
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Figure 6 IFN-g treatment upregulated the expression of cell surface molecules on PBMC-derived adherent cells. (A) PBMC were incubated in the
absence or presence of IFN-g (20ngml
 1) for 2h. After treatment of MMC, the adherent cells were incubated in fresh culture medium for 2 days. (B) For
analysis of the expression of cell surface molecules on the cells, the cells were stained with anti-HLA class I, anti-HLA DP/DQ/DR, anti-human CD86 or
control antibody for 15min, and analysed in a flow cytometry. These experiments were carried out independently at least three times. Data are
representative of the experiments.
Table 1 IFN-g treatment upregulated the expression of cell surface
molecules on PBMC-derived adherent cells
Cell surface markers
HLA class I HLA class II CD86
IFN-g treatment ( ) (+) ( ) (+) ( ) (+)
Donor 4 14.6
a 21.4 41.3 178 17.4 25.2
Donor 5 22.4 37.6 210 688 21.2 35.3
aFigures represent mean fluorescence intensity detected by flow cytometry.
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Moreover, the expanded MAGE-A4-specific Th cells produced
high levels of IFN-g and less IL-4 in two healthy donors tested,
suggested that the Th cells would differentiate into Th1 cells
(Figure 7B). Moreover, the Th cells produced neither IL-10 nor
IL-17, and did not detect Foxp3 expression (data not shown).
Therefore, our developed method may be beneficial to apply
adoptive Th1 cell therapy to clinical study.
Finally, as shown in Figure 8B, we also showed that MAGE-A4
helper epitope peptides were presented to MHC class II molecules
on MAGE-A4-specific Th1 cells to stimulate Th1-derived cytokine
release, which is preferable to induce IFN-g-producing Tc1 cells
essential for eradication of tumour cells.
In conclusion, we first identified MAGE-A4-derived helper
peptides, which will become a good tool for propagating and
activating MAGE-A4 peptide-specific Th1 cells. These findings
would contribute to a clinical trial of adoptive Th1-cell therapy
against MAGE-A4-expressing human cancer in future. Recently,
Hunder et al (2008) reported that NY-ESO-1-specific CD4
þ T cells
into patients with metastatic melanoma caused a great inhibition
of tumour. The new challenge to the adoptive immunotherapy is
now started and we believed that Th1-cell therapy using tumour-
specific Th1 cells expanded with helper epitope peptide would
become a promising strategy for the immunotherapy of human
cancer.
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